Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial
about
Laser Ablation of Recurrent Malignant Gliomas: Current Status and Future Perspective.Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.Advances in the molecular genetics of gliomas - implications for classification and therapy.Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.Immunological effects of chemotherapy and radiotherapy against brain tumors.Angiogenesis inhibitors in tackling recurrent glioblastoma.Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.The benefit of surgical resection in recurrent glioblastoma.Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas.Long-term survivors of glioblastoma: a closer look.From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK).A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN.Treatment of glioblastoma in adults
P2860
Q36196954-80482D6F-978E-45AC-B792-EE8DA6C43591Q38724867-54E2F0FE-2A90-4FB5-9AAC-B92315BCCCA4Q38777058-D6E67833-8EA8-4E8C-8A43-E1AA429FC683Q38909395-75408522-51E2-4102-853B-F91311120AD3Q38947116-8F2F44C9-09A1-44C6-BB50-8FC347772E2EQ39259089-A7A2A49C-324A-4ADA-BD3B-F2E5E1D0ACD0Q39435280-62BA11D5-55A6-4761-955D-359D78C80C4DQ42944471-11DF30E5-3625-427D-971D-27C1BADAACEDQ47100447-D15B4A9C-00AD-4377-998D-BDDA4B7C2AEEQ47128299-E7BDF993-18BB-48D3-8047-B20D630943E3Q47698608-63191F21-954B-483C-BB68-15A9FB13ACF5Q47863423-3C390133-D2C5-4749-A630-CCB61011C29DQ48149391-38D6502C-7DF5-4596-84E2-F5E21587D885Q50049531-D8292E68-BD35-4202-8904-9A5DA2BA2D39Q52638902-E0C1006C-D910-4619-B338-3D962EC4103FQ54980235-258839EF-F603-4705-A5FA-468640F6B61DQ55421741-49B2D7B2-5BD0-4846-A62A-B4CC4DDF0C46Q57174802-104F4385-DACB-45A0-82E2-2B8406D447A5
P2860
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Complete resection of contrast ...... esults from the DIRECTOR trial
@ast
Complete resection of contrast ...... esults from the DIRECTOR trial
@en
type
label
Complete resection of contrast ...... esults from the DIRECTOR trial
@ast
Complete resection of contrast ...... esults from the DIRECTOR trial
@en
prefLabel
Complete resection of contrast ...... esults from the DIRECTOR trial
@ast
Complete resection of contrast ...... esults from the DIRECTOR trial
@en
P2093
P2860
P50
P356
P1433
P1476
Complete resection of contrast ...... esults from the DIRECTOR trial
@en
P2093
Bogdana Suchorska
Christian Senft
Christine Marosi
Hans-Georg Wirsching
Jörg C Tonn
Michael C Sabel
Ralf Ketter
Ulrich Herrlinger
Uwe Schlegel
P2860
P304
P356
10.1093/NEUONC/NOV326
P577
2016-01-27T00:00:00Z